NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S. drugs regulator clamps down on mass production of copies of the in-demand medicine. Noom will offer its version of compounded semaglutide - the active ingredient in Wegovy and diabetes drug Ozempic - as part of a program personalized for patients, which it says will comply with changing U.S. Food and Drug Administration regulations. Demand for the new generation of highly effective but pricey weight-loss drugs has catapulted sales at Noom and rival telehealth sites including Hims & Hers, WeightWatchers and Ro over the past two years.
Home Depot beats sales estimates on stable demand, maintains forecast
Shares of the Atlanta-based retailer jumped more than 2% in premarket trading as the company also kept its fiscal 2025 forecast unchanged, with a sales growth target of 2.8%. Home Depot has benefited from demand for tools used in do-it-yourself house projects, repair and maintenance ahead of the spring season, even as budget constraints weighed on larger home renovation activities.
Reuters
•
53 minutes ago
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the…
"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next year.
Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.
The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims &…
Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
